ImmunoPrecise Antibodies Ltd.

IPA · NASDAQ

$1.62 +2.53% (+$0.04)

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Valuation

N/A

EV/EBITDA N/A

P/S N/A

P/B N/A

Growth

N/A

Rev. growth N/A

FCF growth N/A

Book val. growth N/A

Profitability

N/A

Net margin N/A

Op. margin N/A

FCF margin N/A

Quality

N/A

ROE N/A

ROA N/A

Asset turnover N/A

Debt

N/A

Current ratio N/A

Int. coverage N/A

Net debt/EBITDA N/A

Stability

73 /100

Stable

Beta 0.49x

EPS volatility N/A

Profitable years N/A

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about IPA

Online

About the company

ImmunoPrecise Antibodies Ltd. (IPA) is a biotechnology company specializing in the development and production of monoclonal antibodies for research, diagnostics, and therapeutic purposes. Headquartered in Canada, the company operates globally, offering services related to antibody generation and characterization, including the development of anti-cancer and immunotherapeutic antibodies. ImmunoPrecise Antibodies focuses on providing high-quality and specialized products for various industries and research institutions. Shares of ImmunoPrecise Antibodies Ltd. (IPA) are listed on the Canadian stock exchange and can be an appealing choice for investors seeking investment opportunities in the biotechnology and healthcare research sector.

Sector

Healthcare

Industry

Biotechnology

CEO

Jennifer Lynne Bath

Employees

Headquarters

Austin

⌘ K

StockBot Live

Market situation Europe

European markets drift lower as oil prices rebound

DAX -0.13% and FTSE 100 -0.10% dip as oil prices rebound. CAC 40 is +0.01%. US futures signal a muted open.

Ask about this

StockBot knows 80,000+ stocks worldwide